Launched in 2024 from the assets and expertise of Neurokinetics and Neurolign, Spryson develops AI-powered neurological diagnostic technology built around high-precision eye tracking, vestibular assessment, and clinical analysis. Its NeuroAI platform brings research-grade tools into clinical settings, supporting brain-health screening and care for conditions ranging from concussion and balance disorders to Parkinson’s disease. The company says its technology is used by more than 200 customer sites and draws on a legacy spanning over two decades, 30-plus patents, and more than 60 peer-reviewed publications.
FDA Clearance for DX Series Software (VEST)
Compliance program
FDA Breakthrough Device Status Application for PD-Check
Compliance program
BrainScope Company, IncFounded in 2006, BrainScope develops medical neurotechnology that converts brain electrical activity (EEG) into objective, point-of-care assessments for brain health. Its FDA-cleared system was the first AI/machine-learning medical device cleared in neurology and is used to assess head injuries for the likelihood of brain bleeds and concussion without radiation. The company is now extending its EEG-based platform into digital biomarkers for conditions including stroke and cognitive decline.ROCKVILLE, MD
QuantalXFounded by neuroscientists Iftach Dolev, PhD, and Hilla Fogel, PhD, QuantalX develops neurodiagnostic technology that measures brain-network function in real time. Its Delphi-MD system combines focused magnetic stimulation, electrophysiological recording, and algorithmic analysis to give clinicians quantitative functional insights alongside conventional evaluation. The FDA De Novo-authorized platform is used in clinics and research sites across Europe, Asia, and North America.New York, NY
AI OpticsAI Optics develops portable retinal-imaging hardware and AI-based screening software that brings eye-disease screening into primary care, retail health, home-based care, and other point-of-care settings. Founded by an NYU-trained physician who saw the consequences of limited screening access, the company built its FDA-cleared Sentinel Camera from scratch and is developing Sentinel Pro to run disease-screening modules directly on the handheld device. The New York-based team combines medical-device engineering experience with expertise in optical systems, embedded devices, and AI algorithms.NEW YORK, NY
Cognivue, IncCognivue develops FDA-cleared digital cognitive assessment devices for earlier detection of potential cognitive impairment in healthcare settings. Conceived and developed in part by President and CEO Paul W. Estes beginning in 2009, its adaptive-psychophysics technology customizes self-administered testing to each patient’s visual and motor capabilities while collecting more than 130,000 data points. Based in Victor, New York, Cognivue supports clinical use and research through products including the five-minute Thrive screen and the more comprehensive Clarity assessment.VICTOR, NY